What is Claimed Is:

1. The present invention relates to compounds of formula I:



I

its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof wherein:

R_1 and R_2 independently represent
hydrogen, NR_5R_6, $CR_7R_8R_9$, $C(R)_2OR_{14}$, CH_2NHR_{14}, $C(=O)R_{13}$, $C(=NOH)H$, $C(=NOR_{13})H$, $C(=NOR_{13})R_{13}$, $C(=NOH)R_{13}$, $C(=O)N(R_{13})_2$, $C(=NOH)N(R_{13})_2$, $NHC(=X_1)N(R_{13})_2$, $(C=NH)R_7$, $N(R_{13})C(=X_1)N(R_{13})_2$, $COOR_{13}$, SO_2R_{14}, $N(R_{13})SO_2R_{14}$, $N(R_{13})COR_{14}$, $(C_{1\text{-}6}alkyl)CN$, CN, $CH=C(R)_2$, $C(R_4)_2X_1SiR_{16}$, $(CH_2)_pOH$, $C(=O)CHR_{13}$, $C(=NR_{13})R_{13}$, $NR_{10}C(=X_1)R_{13}$; or $C_{5\text{-}10}$ heterocycle optionally substituted with 1-3 groups of R_7, which may be attached through either a carbon or a heteroatom;

A represents C (when --- is present), CH or N (when --- is not present);

--- represents a bond;



represents aryl or heteroaryl, heterocycle, heterocyclyl or heterocyclic; provided that in the case of a heteroaryl, heterocycle, heterocyclyl or heterocyclic, a cyclopropyl is not attached to a nitrogen atom on the ring;

R_x represents hydrogen or C_{1-6} alkyl;

R_3 represents  which is an optionally substituted aromatic heterocyclic group containing at least one nitrogen in the ring and which is attached through a bond on any N, and which is unsubstituted or contains 1 to 3 substituents of R_7

R_4 and R_{4a} independently represent
hydrogen,
halogen,
C_{1-6} alkoxy, or
C_{1-6} alkyl

r and s independently are 1-3, with the provision that when $(R_{4a})_s$ and $(R_4)_r$ are attached to an Ar or HAr ring the sum of r and s is less than or equal to 4;

R_5 and R_6 independently represent
hydrogen, C_{1-6} alkyl optionally substituted with 1-3 groups of halogen, CN, OH, C_{1-6} alkoxy, amino, imino, hydroxyamino, alkoxyamino, C_{1-6} acyloxy, C_{1-6} alkylsulfenyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, aminosulfonyl, C_{1-6} alkylaminosulfonyl, C_{1-6} dialkylaminosulfonyl, 4-morpholinylsulfonyl, phenyl, pyridine, 5-isoxazolyl, ethylenyloxy, or ethynyl, said phenyl and pyridine optionally substituted with 1-3 halogen, CN, OH, CF_3, C_{1-6} alkyl or C_{1-6} alkoxy; C_{1-6} acyl optionally substituted with 1-3 groups of halogen, OH, SH, C_{1-6} alkoxy, naphthalenoxy, phenoxy, amino, C_{1-6} acylamino, hydroxylamino, alkoxylamino, C_{1-6} acyloxy, aralkyloxy, phenyl, pyridine, C_{1-6} alkylcarbonyl, C_{1-6} alkylamino, C_{1-6} dialkylamino, C_{1-6} hydroxyacyloxy, C_{1-6} alkylsulfenyl, phthalimido, maleimido, succinimido, said phenoxy, phenyl and pyridine optionally substituted with 1-3 groups of halo, OH, CN, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl;
C_{1-6} alkylsulfonyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy, amino, hydroxylamino, alkoxylamino, C_{1-6} acyloxy, or phenyl; said phenyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl; arylsulfonyl optionally substituted with 1-3 of halogen, C_{1-6} alkoxy, OH or C_{1-6} alkyl;

C_{1-6} alkoxycarbonyl optionally substituted with 1-3 of halogen, OH, C_{1-6} alkoxy, C_{1-6} acyloxy, or phenyl, said phenyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, CF_3 or C_{1-6} alkyl; aminocarbonyl, C_{1-6} alkylaminocarbonyl or C_{1-6} dialkylaminocarbonyl, said alkyl groups optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy or phenyl, five to six membered heterocycles optionally substituted with 1-3 groups of halogen, OH, CN, amino, C_{1-6} acylamino, C_{1-6} alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, C_{1-6} alkoxy, C_{1-6} acyloxy or C_{1-6} alkyl, said alkyl optionally substituted with 1-3 groups of halogen, or C_{1-6} alkoxy;
C_{3-6} cycloalkylcarbonyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy or CN; benzoyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy, C_{1-6} alkyl, CF_3, C_{1-6} alkanoyl, amino or C_{1-6} acylamino; pyrrolylcarbonyl optionally substituted with 1-3 of C_{1-6} alkyl; C_{1-2} acyloxyacetyl where the acyl is optionally substituted with amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, 4-morpholino, 4-aminophenyl, 4-(dialkylamino)phenyl, 4-(glycylamino)phenyl; or R_5 and R_6 taken together with any intervening atoms can form a 3 to 7 membered heterocyclic ring containing carbon atoms and 1-2 heteroatoms independently chosen from O, S, SO, SO_2, N, or NR_8;

R_7 represent
hydrogen, halogen, CN, CO_2R, $CON(R)_2$, CHO, CH_2NHAc, C(=NOR), OH, C_{1-6} alkoxy, C_{1-6} alkyl, alkenyl, $(CH_2)_n$amino, $(CH_2)_nC1-6$ alkylamino, C_{1-6} dialkylamino, hydroxylamino or C_{1-2} alkoxyamino all of which can be optionally substituted on the nitrogen with C_{1-6} acyl, C_{1-6} alkylsulfonyl or C_{1-6} alkoxycarbonyl, said acyl and alkylsulfonyl optionally substituted with 1-2 of halogen or OH;

R_8 and R_9 independently represents
H, CN,
C_{1-6} alkyl optionally substituted with 1-3 halogen, CN, OH, C_{1-6} alkoxy, C_{1-6} acyloxy, or amino,
phenyl optionally substituted with 1-3 groups of halogen, OH, C_{1-6} alkoxy; or

R_7 and R_8 taken together can form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO_2, NH, and NR_8;

X_1 represents O, S or NR_{13}, NCN, NCO_2R_{16}, or NSO_2R_{14}

R_{10} represents hydrogen, C_{1-6} alkyl or CO_2R_{15};

Each R_{13} represents independently hydrogen, C_{1-6} alkyl, C_{6-10} aryl, NR_5R_6, SR_8, $S(O)R_8$, $S(O)_2$ R_8, CN, OH, C_{1-6} alkylS(O)R, C_{1-6} alkoxycarbonyl, hydroxycarbonyl, C_{1-6} acyl, C_{3-7} membered carbon ring optionally interrupted with 1-4 heteroatoms chosen from O, S, SO, SO_2, NH and NR_8 where said C_{1-6} alkyl, aryl or C_{1-6} acyl groups may be independently substituted with 0-3 halogens, hydroxy, $N(R)_2$, CO_2R, C_{6-10} aryl, C 5-10 heteroaryl, or C_{1-6} alkoxy groups;

When two R_{13} groups are attached to the same atom or two adjacent atoms they may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO_2, NH, and NR_8;

R represents hydrogen or C_{1-6} alkyl;

R_{14} represents amino, C_{1-6} alkyl, C_{1-6} haloalkyl, five to six membered heterocycles or phenyl, said phenyl and heterocycles optionally substituted with 1-3 group of halo, C_{1-6} alkoxy, C_{1-6} acylamino, or C_{1-6} alkyl, hydroxy and/or amino, said amino and hydroxy optionally protected with an amino or hydroxy protecting group;

R_{15} is C_{1-6} alkyl or benzyl said benzyl optionally substituted with 1-3 groups of halo, OH, C_{1-6} alkoxy, amino, C_{1-6} acylamino, or C_{1-6} alkyl;

R_{16} is hydrogen, C_{5-10}heteroaryl, C $_{6-10}$aryl, said heteroaryl and aryl optionally substituted with 1-3 groups of R_7;

m, n, p and q represents 0-1.

2. A compound according to claim 1 wherein R_1 and R_2 independently represent H, NR_5R_6, CN, OH, $C(R)_2OR_{14}$, $NHC(=X1)N(R_{13})_2$, $C(=NOH)N(R_{13})_2$, $NR_{10}C(=X_1)R_{13}$ or $CR_7R_8R_9$.

3. A compound according to claim 2 wherein 

is phenyl, pyridine, pyrimidine, or piperidine.

4. A compound according to claim 3 wherein one of R_1 and R_2 is H and the other is NR_5R_6; H and the other is CN; or H and the other is $NR_{10}C(=X_1)R_{13}$.

5. A compound according to claim 4 wherein A is C, --- is present, and $Z=(O)_n$ where n=0; A is C, --- is not present and Z=H, OH or halogen or A is N, --- is not present and $Z=(O)_n$ where n=1.

6. A compound according to claim 5 wherein R_3 is 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, tetrazole, pyrazole, or imidazole, any of which may contain 1 to 3 substitutents of R_7.

7. A compound which is:

1-[5(R)-3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3,5-difluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-[(t-butyldiphenylsilyl)oxy]methylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-[(t-butyldiphenylsilyl)oxy]methylbicyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-hydroxyoxymethylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[3-fluoro-4-[(1α,5α,6α)-6-hydroxyoxymethylbicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,
1-[5(R)-3-[4-[(1α,5α,6α)-6-cyanobicyclo[3.1.0]hex-2-en-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

1-[5(R)-3-[4-[(1α,5α,6α)-6-cyanobicyclo[3.1.0]hex-2-en-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole,

or its enantiomer, diastereomer, or pharmaceutically acceptable salt, hydrate or prodrug thereof.

8. A pharmaceutical composition comprised of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier and optionally a in combination with a vitamin selected from the group consisting vitamin B2, vitamin B6, vitamin B12 and folic acid.

9. A method of treating or preventing a bacterial infection in a mammalian patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 1.

10. A method of treating or preventing bacterial infection or an oxazolidinone-associated side effect by administering an effective amount of a compound of formula I of claim 1 and an effective amount of one or more of a vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12 and folic acid to a patient in need thereof.

11. A method according to claim 10 for treating or preventing oxazolidinone-associated normocyctic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis, hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis by administering an effective amount of vitamin B2 to a patient in need thereof.